Carfilzomib plus Filanesib versus Carfilzomib in Patients with Advanced Multiple Myeloma

Conference Correspondent  - TOP - ASH 2015 - Multiple Myeloma, Conference Correspondent

Filanesib (ARRY-520) is a first-in-class kinesin spindle protein (KSP) inhibitor that is being evaluated in combination with the proteasome inhibitor carfilzomib versus carfilzomib alone in an ongoing, randomized, open-label phase 2 study in patients with relapsed and/or refractory multiple myeloma (RRMM); Zonder and colleagues presented preliminary results of this trial.1 A total of 77 patients who were carfilzomib-naïve, had received at least 2 prior regimens, including bortezomib and an immunomodulatory drug (IMiD), and were refractory to the last regimen were enrolled in the trial. Patients were randomized 2:1 to receive either carfilzomib (20/27 mg/m2 intravenously [IV]) plus filasenib (1.25 mg/m2 IV) (arm A; n = 52) or carfilzomib alone (arm B; n = 25); of these, 50 patients were evaluable for this analysis. Of the patients in arm A, 47% had high-risk cytogenetics compared with 44% in arm B. In addition, 60% of the patients in both arms were dual-refractory to an IMiD and bortezomib.

In this heavily pretreated patient population (median prior regimens 4-5 for the 2 arms), carfilzomib/filanesib treatment resulted in an increased median progression-free survival (PFS) of 8.5 months versus 3.7 months for carfilzomib alone. The overall response rate (ORR) was 28%, including 3 very good partial responses and 9 partial responses, compared with an ORR of 12% with carfilzomib alone. Notably, the patient subset with double-refractory disease to IMiDs and bortezomib achieved an ORR of 33% with both carfilzomib/filanesib and carfilzomib alone. Low levels of alpha-1-acid glycoprotein (AAG) was associated with higher ORR and PFS rates in both arms.

Grade 3/4 hematologic laboratory abnormalities were higher with carfilzomib/filanesib therapy and included neutropenia (26% vs 12%) and thrombocytopenia (31% vs 12%). Dyspnea and fatigue were the only grade 3/4 nonhematologic adverse events reported (5% vs 8% and 7% vs 4%, respectively). Based on these preliminary study results, the authors concluded that carfilzomib plus filanesib was a promising steroid-sparing treatment option for patients with RRMM, including those with double-refractory disease. In addition, patients with high AAG levels may be less likely to respond to either filanesib or carfilzomib.

  1. Zonder JA, et al. ASH 2015. Abstract 728.
Related Items
Sexual Dysfunction After Cancer: Why Aren’t We Talking About It?
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
The Importance of Compassion: Perspective From a Lifelong Patient
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Using a Team Approach to Tackle Opioid Abuse in Patients with Cancer
Meg Barbor, MPH
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Addressing the Second Victim Phenomenon
Charles Bankhead
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in ONS 2018, Conference Correspondent
Palliative Care Use Dismal Among Patients with Hematologic Malignancies
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Palliative Care, Hematologic Cancers
Oral Multiple Myeloma Medication Linked to Decreased Productivity Loss
Chase Doyle
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, ASH, Multiple Myeloma
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates, ASH
“Superhero” Navigators Convene at the 8th Annual Navigation & Survivorship Conference
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in AONN+ News, Conference Correspondent
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Measuring Financial Well-Being in Cancer Survivorship
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Survivorship
Last modified: December 5, 2017